155 related articles for article (PubMed ID: 1401624)
1. Effects of sotalol on the signal-averaged electrocardiogram in patients with sustained ventricular tachycardia: relation to suppression of inducibility and changes in tachycardia cycle length.
Freedman RA; Karagounis LA; Steinberg JS
J Am Coll Cardiol; 1992 Nov; 20(5):1213-9. PubMed ID: 1401624
[TBL] [Abstract][Full Text] [Related]
2. Effects of procainamide on the signal-averaged electrocardiogram in relation to the results of programmed ventricular stimulation in patients with sustained monomorphic ventricular tachycardia.
Kulakowski P; Bashir Y; Heald S; Paul V; Anderson MH; Gibson S; Malik M; Camm AJ
J Am Coll Cardiol; 1993 May; 21(6):1428-39. PubMed ID: 8473652
[TBL] [Abstract][Full Text] [Related]
3. Electrocardiographic predictors in the ESVEM trial: unsustained ventricular tachycardia, heart period variability, and the signal-averaged electrocardiogram.
Anderson KP; Bigger JT; Freedman RA
Prog Cardiovasc Dis; 1996; 38(6):463-88. PubMed ID: 8638028
[TBL] [Abstract][Full Text] [Related]
4. Absence of change of signal-averaged electrocardiogram identifies patients with ventricular arrhythmias who are non-responders to amiodarone.
Brembilla-Perrot B; Claudon O; Houriez P; Beurrier D; Suty-Selton C
Int J Cardiol; 2002 Apr; 83(1):47-55. PubMed ID: 11959384
[TBL] [Abstract][Full Text] [Related]
5. Noninvasive prediction of efficacy of type IA antiarrhythmic drugs by the signal-averaged electrocardiogram in patients with coronary artery disease and sustained ventricular tachycardia.
Hopson JR; Kienzle MG; Aschoff AM; Shirkey DR
Am J Cardiol; 1993 Aug; 72(3):288-93. PubMed ID: 8342506
[TBL] [Abstract][Full Text] [Related]
6. Correlation between inducibility of sustained ventricular tachycardia and QRS duration.
Brembilla-Perrot B
Eur Heart J; 1994 Jan; 15(1):26-31. PubMed ID: 8174580
[TBL] [Abstract][Full Text] [Related]
7. Time domain analysis of the signal averaged electrocardiogram in patients with a conduction defect or a bundle branch block.
Gatzoulis KA; Carlson MD; Biblo LA; Rizos I; Gialafos J; Toutouzas P; Waldo AL
Eur Heart J; 1995 Dec; 16(12):1912-9. PubMed ID: 8682026
[TBL] [Abstract][Full Text] [Related]
8. Selective prolongation of QRS late potentials by sodium channel blocking antiarrhythmic drugs: relation to slowing of ventricular tachycardia. Electrophysiologic Study Versus Electrocardiographic Monitoring Trial (ESVEM) Investigators.
Freedman RA; Steinberg JS
J Am Coll Cardiol; 1991 Apr; 17(5):1017-25. PubMed ID: 1848871
[TBL] [Abstract][Full Text] [Related]
9. The effects of type I antiarrhythmic drugs on the signal-averaged electrocardiogram in patients with malignant ventricular arrhythmias.
Greenspon AJ; Kidwell GA; DeCaro M; Hessen S
Pacing Clin Electrophysiol; 1992 Oct; 15(10 Pt 1):1445-53. PubMed ID: 1383955
[TBL] [Abstract][Full Text] [Related]
10. Prediction of antiarrhythmic efficacy of class I and III agents in patients with ventricular tachycardia by signal-averaged ECG analysis.
Kulakowski P; Bashir Y; Heald S; Paul V; Anderson MH; Gibson S; Malik M; Camm AJ
Pacing Clin Electrophysiol; 1992 Nov; 15(11 Pt 2):2116-21. PubMed ID: 1279610
[TBL] [Abstract][Full Text] [Related]
11. Performance of the signal-averaged electrocardiogram: relation to baseline QRS duration.
Okin PM; Stein KM; Lippman N; Lerman BB; Kligfield P
Am Heart J; 1995 May; 129(5):932-40. PubMed ID: 7732982
[TBL] [Abstract][Full Text] [Related]
12. Electrophysiologic mechanisms of antiarrhythmic efficacy of a sotalol and class Ia drug combination: elimination of reverse use dependence.
Lee SD; Newman D; Ham M; Dorian P
J Am Coll Cardiol; 1997 Jan; 29(1):100-5. PubMed ID: 8996301
[TBL] [Abstract][Full Text] [Related]
13. Sotalol and type IA drugs in combination prevent recurrence of sustained ventricular tachycardia.
Dorian P; Newman D; Berman N; Hardy J; Mitchell J
J Am Coll Cardiol; 1993 Jul; 22(1):106-13. PubMed ID: 8509529
[TBL] [Abstract][Full Text] [Related]
14. Electrocardiographic correlates of spontaneous termination of ventricular tachycardia in patients with coronary artery disease.
Duff HJ; Mitchell LB; Gillis AM; Sheldon RS; Chudleigh L; Cassidy P; Chiamvimonvat N; Wyse DG
Circulation; 1993 Sep; 88(3):1054-62. PubMed ID: 8353867
[TBL] [Abstract][Full Text] [Related]
15. Multicenter trial of sotalol compared with procainamide in the suppression of inducible ventricular tachycardia: a double-blind, randomized parallel evaluation. Sotalol Multicenter Study Group.
Singh BN; Kehoe R; Woosley RL; Scheinman M; Quart B
Am Heart J; 1995 Jan; 129(1):87-97. PubMed ID: 7817931
[TBL] [Abstract][Full Text] [Related]
16. Antiarrhythmic effects of selective prolongation of refractoriness. Electrophysiologic actions of sematilide HCl in humans.
Sager PT; Nademanee K; Antimisiaris M; Pacifico A; Pruitt C; Godfrey R; Singh BN
Circulation; 1993 Sep; 88(3):1072-82. PubMed ID: 8353869
[TBL] [Abstract][Full Text] [Related]
17. Electrophysiologic variables characterizing the induction of ventricular tachycardia versus ventricular fibrillation after myocardial infarction: relation between ventricular late potentials and coupling intervals for the induction of sustained ventricular tachyarrhythmias.
Martinez-Rubio A; Shenasa M; Borggrefe M; Chen X; Benning F; Breithardt G
J Am Coll Cardiol; 1993 Jun; 21(7):1624-31. PubMed ID: 8496529
[TBL] [Abstract][Full Text] [Related]
18. Electrophysiologic and antiarrhythmic efficacy of oral sotalol for sustained ventricular tachyarrhythmias: evaluation by programmed stimulation and ambulatory electrocardiogram.
Steinbeck G; Bach P; Haberl R
J Am Coll Cardiol; 1986 Oct; 8(4):949-58. PubMed ID: 3760368
[TBL] [Abstract][Full Text] [Related]
19. Randomized crossover comparison of the electrophysiologic and antiarrhythmic efficacy of oral cibenzoline and sotalol for sustained ventricular tachycardia.
Hoffmann E; Mattke S; Haberl R; Steinbeck G
J Cardiovasc Pharmacol; 1993 Jan; 21(1):95-100. PubMed ID: 7678686
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and electrophysiologic effects of oral sotalol in patients with sustained ventricular tachycardia caused by coronary artery disease.
Kus T; Campa MA; Nadeau R; Dubuc M; Kaltenbrunner W; Shenasa M
Am Heart J; 1992 Jan; 123(1):82-9. PubMed ID: 1729853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
